Yu, F., et al. (2007) Involvement of the CDK2-E2F1 Pathway in Cisplatin Cytotoxicity in Vitro and in Vivo. American Journal of Physiology-Renal Physiology, 293, F52-F59.
https://doi.org/10.1152/ajprenal.00119.2007

has been cited by the following article:

• TITLE: The Role for AVE0991 (MAS-Receptor Angiotensin II (1-7) Agonist) in Reducing Cisplatin-Induced Acute Kidney Injury on C57BL/6 Mice

  AUTHORS: Chris Mathew

  KEYWORDS: Cisplatin, Acute Kidney Injury, AKI, Cisplatin-Induced Acute Kidney Injury, Nephrotoxicity, Renal Renin Angiotensin System, RAS, AVE0991, MAS-Receptor Angiotensin II (1-7) Agonist

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.1, January 31, 2023

  ABSTRACT: Acute Kidney Injury (AKI) is a condition that causes nephrotoxicity in kidney tissues due to cisplatin-induced cancer treatments. Hence, it is proposed in this review that AVE0991 (a MAS-receptor Angiotensin II (1-7) agonist) may reduce cisplatin-induced acute kidney injury by promoting nitric oxide production.